Anna Levine Taub's research while affiliated with Northeastern University and other places

Publications (5)

Article
We present two new findings based on annual antipsychotic US prescribing data from IMS Health on 2867 psychiatrists who wrote 50 or more prescriptions in 2007. First, many of these psychiatrists have prescription patterns that are statistically significantly different than random draws from national market shares for prescriptions by psychiatrists....
Article
Objective: Physician antipsychotic prescribing behavior may be influenced by comparative effectiveness evidence, regulatory warnings, and formulary and other restrictions on these drugs. This study measured changes in the degree to which physicians are able to customize treatment choices and changes in physician preferences for specific agents aft...
Article
Objective The authors examined physician adoption of second-generation antipsychotic medications and identified physician-level factors associated with early adoption. Methods The authors estimated Cox proportional-hazards models of time to adoption of nine second-generation antipsychotics by 30,369 physicians who prescribed antipsychotics between...
Article
Full-text available
Physicians prescribing drugs for patients with schizophrenia and related conditions are remarkably concentrated in their choice among antipsychotic drugs. In 2007 the single antipsychotic drug prescribed by a physician accounted for 66% of all antipsychotic prescriptions written by that physician. Which particular branded antipsychotic was the pres...
Article
First I empirically show how market structure influences the split of producer surplus innovators receive for successful innovation in the biotechnology pharmaceutical industry. After identifying the drivers of firms' values for adding a new drug to their product portfolio, I show that when the distribution of marketing rights for products in a phy...

Citations

... 23 Additionally, the volume of prescribed drugs influences the tendency to concentrate prescriptions on certain drugs. 24 First evidence on the role of biosimilar prescription targets to influence biosimilar share and use in Germany suggests large heterogeneity across all German regions in the use of prescription targets and average effects across regions were small to zero. 25 This study adds to previous evidence by identifying the treatment effects for prescription target regulations aiming to increase biosimilar utilization on the regional level. We used a rich data set containing routinely collected claims data of dispensed prescriptions in ambulatory care by physicians practicing within the statutory health insurance (SHI) in Germany. ...
... 11,12 Due to their metabolic adverse effects, which can drive patients into partial and/or total nonadherence to treatment, efforts to reduce the use of AAP have been made. [13][14][15] Nevertheless, they remain the reference medications in the treatment of schizophrenia. 16 Given the wide use of AAP, a deeper understanding of the mechanisms leading to AIWG and/or metabolic impairments is essential. ...
... Medium to high quality studies suggested younger [33,48,53,62] or older [27,42], male [23,42,48,85], graduating from a top-20 medical [23,62] or foreign medical school [48] prescribers were earlier adopters. Other medium to high quality studies reported that age [29,42,48], gender [29,62], prescribers' length of practice [35,85], graduating from a top-20 medical school [48,62] did not influence prescribing decisions. ...
... Although these results cannot explicate the motivations of the prescribers who had their payments cut, the direction of these results is broadly consistent with prior literature on "learning by doing" in drug prescribing. Physicians tend to be more diffuse in their prescribing early in their careers and become more concentrated over time as they learn and develop preferences for different treatments (Taub, Kolotilin, Gibbons, & Berndt, 2011). A shock to a physician's preferences-where he previously concentrated his prescriptions on a particular drug that he no longer has a strong preference for-could potentially lead to physicians temporarily increasing their prescriptions of other drugs, both branded and generic. ...